All In Biotech

BLA 761094 · Dompe Farmaceutici

Oxervate

Cenegermin-Bkbj · Ophthalmic · Recombinant Human Nerve Growth Factor

NovelBreakthrough therapyPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Oct 20, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

Aug 22, 2018

Approved uses

1

Original approval plus efficacy supplements

Registered trials

20

4 Phase 3, 2 recruiting

FAERS reports

13,495

1,498 serious, 220 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 11, 2026.

OXERVATE ® (cenegermin-bkbj) ophthalmic solution 0.002% is indicated for the treatment of neurotrophic keratitis. OXERVATE is a recombinant human nerve growth factor indicated for the treatment of neurotrophic keratitis. ( 1 )

Mechanism: Nerve growth factor is an endogenous protein involved in the differentiation and maintenance of neurons, which acts through specific high-affinity (i.e., TrkA) and low-affinity (i.e. p75NTR) nerve growth factor receptors in the anterior segment of the eye to support corneal innervation and integrity.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 22, 2018 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLabelLetterReview
1 products under this application
  • OXERVATE · CENEGERMIN-BKBJ 0.002%(20MCG/ML) · SOLUTION, OPHTHALMIC · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Cenegermin" as an intervention, any sponsor and status, largest first.

All 20 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • eye pain6,508
  • eye irritation2,111
  • product dose omission issue1,456
  • ocular hyperaemia1,360
  • photophobia1,209
  • vision blurred1,053
  • eye swelling959
  • wrong technique in product usage process949
  • ocular discomfort908
  • lacrimation increased822
  • eyelid pain797
  • headache773

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20171
2019488
2020661
20211,094
20221,926
20232,337
20242,274
20253,179
20261,535

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Oxervate (Cenegermin-Bkbj)

2024 spending

$715M

Beneficiaries

4,781

18,294 claims

Per beneficiary

$149,456

$2,011.76 per unit

View as table
YearSpending
2020$215,418,307
2021$274,796,161
2022$367,261,094
2023$493,161,481
2024$714,549,320

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 5 on PubMed

Sponsor: Dompe Farmaceutici

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.